NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorośli (od 18 lat) z potwierdzonym histopatologicznie czerniakiem skóry (stadium IIB, IIC lub III N1c).
- •Pacjenci leczeni w ramach standardowej opieki medycznej.
✗ Disqualifies
- •Brak wystarczających danych medycznych lub wyników obserwacji.
- •Pacjenci, którzy nie wyrazili świadomej zgody na udział w badaniu (w przypadku części badania prospektywnego).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
AC Camargo Cancer Center
São Paulo, Brazil
Trial contact
MILTON SILVA
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.